AT 02 - Amylon Therapeutics
Alternative Names: AT-02 - Amylon TherapeuticsLatest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator Amylon Therapeutics
- Class Neuroprotectants; Oligonucleotides; RNA
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Spinal muscular atrophy
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for research development in Spinal-muscular-atrophy in Netherlands
- 23 Sep 2020 Early research in Spinal muscular atrophy in Netherlands (unspecified route) before September 2020 (Amylon Therapeutics pipeline, September 2020)